Distinguished in Agranulocytosis

Dr. Bijal Shah

Hematology | Oncology
H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc
12902 Usf Magnolia Dr, 
Tampa, FL 
Offers Telehealth
20 Years of Experience
Distinguished in Agranulocytosis
H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc
12902 Usf Magnolia Dr, 
Tampa, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Bijal Shah is a Hematologist and an Oncologist in Tampa, Florida. Dr. Shah has been practicing medicine for over 20 years and is rated as a Distinguished provider by MediFind in the treatment of Agranulocytosis. His top areas of expertise are Mantle Cell Lymphoma (MCL), Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 171 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Agranulocytosis.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in FL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

H LEE MOFFITT CANCER CTR AND RES INST LIFE TIME CANCER SCRN CTR INC
12902 Usf Magnolia Dr, Tampa, FL 33612

Additional Areas of Focus

Dr. Shah has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination With Pneumococcal 13-valent Conjugate Vaccine Before and After CD19-targeted CAR T-cell Immunotherapy
Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination With Pneumococcal 13-valent Conjugate Vaccine Before and After CD19-targeted CAR T-cell Immunotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2026
Intervention Type: Biological
Study Drugs: Pneumococcal conjugate vaccine (PCV13), CD19 targeted CAR T Cell Therapy
Study Phase: Phase 2
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
A Phase 2 Study to Assess the Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Parameters of Umbralisib in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
A Phase 2 Study to Assess the Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Parameters of Umbralisib in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Terminated
Publish Date: January 06, 2026
Intervention Type: Drug
Study Drug: Umbralisib
Study Phase: Phase 2
A Phase I Study of Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
A Phase I Study of Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
Enrollment Status: Completed
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drugs: CC-486, Duvelisib
Study Phase: Phase 1
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Biological
Study Drugs: Cyclophosphamide, Fludarabine, CD19-Positive CAR-T Cells
Study Phase: Phase 1/Phase 2
A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Other, Drug
Study Drug: Sapanisertib
Study Phase: Phase 2
A Single-Arm, Open-Label Phase 2 Pilot Study of Vyxeos (CPX-351) in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
A Single-Arm, Open-Label Phase 2 Pilot Study of Vyxeos (CPX-351) in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
Enrollment Status: Completed
Publish Date: December 12, 2024
Intervention Type: Drug
Study Drugs: Cytarabine, Daunorubicin
Study Phase: Phase 2
A Study of the Selective HDAC6 Inhibitor, ACY-1215, for the Treatment of Patients With Relapsed or Refractory Lymphoid Malignancies
A Study of the Selective HDAC6 Inhibitor, ACY-1215, for the Treatment of Patients With Relapsed or Refractory Lymphoid Malignancies
Enrollment Status: Terminated
Publish Date: August 06, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Investigator-Initiated Phase I/II Clinical Trial of Selinexor (KPT-330) and Liposomal Doxorubicin for Relapsed and Refractory Multiple Myeloma
Investigator-Initiated Phase I/II Clinical Trial of Selinexor (KPT-330) and Liposomal Doxorubicin for Relapsed and Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: January 04, 2023
Intervention Type: Drug
Study Drugs: Selinexor, Liposomal Doxorubicin, Dexamethasone
Study Phase: Phase 1/Phase 2
A Phase 1 Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma
A Phase 1 Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma
Enrollment Status: Terminated
Publish Date: August 25, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

1 Total Publications

Thyroid cytology: The reality before and after the introduction of ultrasound classification systems for thyroid nodules.
Thyroid cytology: The reality before and after the introduction of ultrasound classification systems for thyroid nodules.
Journal: Endocrinologia, diabetes y nutricion
Published: April 12, 2022
Similar Doctors
Distinguished in Agranulocytosis
Dr. Rami S. Komrokji
Hematology | Oncology
Distinguished in Agranulocytosis
Dr. Rami S. Komrokji
Hematology | Oncology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
888-860-2778
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rami Komrokji is a Hematologist and an Oncologist in Tampa, Florida. Dr. Komrokji is rated as an Elite provider by MediFind in the treatment of Agranulocytosis. His top areas of expertise are Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Sideroblastic Anemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Komrokji is currently accepting new patients.

Distinguished in Agranulocytosis
Dr. Lubomir Sokol
Hematology | Oncology
Distinguished in Agranulocytosis
Dr. Lubomir Sokol
Hematology | Oncology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
888-860-2778
Languages Spoken:
English, Czech, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Lubomir Sokol is a Hematologist and an Oncologist in Tampa, Florida. Dr. Sokol is rated as an Elite provider by MediFind in the treatment of Agranulocytosis. His top areas of expertise are T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Sokol is currently accepting new patients.

Distinguished in Agranulocytosis
Dr. Jeffrey Lancet
Hematology Oncology | Hematology | Oncology
Distinguished in Agranulocytosis
Dr. Jeffrey Lancet
Hematology Oncology | Hematology | Oncology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
888-860-2778
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeffrey Lancet is a Hematologist Oncology specialist and a Hematologist in Tampa, Florida. Dr. Lancet is rated as an Elite provider by MediFind in the treatment of Agranulocytosis. His top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Bone Marrow Aspiration, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shah's expertise for a condition
ConditionClose
View All 15 Distinguished Conditions
View All 14 Advanced Conditions
View All 45 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile